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A b s t r a c t  
The present study is based on development and evaluation of gastroretentive floating tablets of 
metoprolol succinate by direct compression method, to increase the oral bioavailability of MS. 
For this, we used a combination of two different hydrophilic polymers that is polyethylene oxide 
PEO N-80 (X1) and hydroxyethylcellulose HEC (X2) as independent variables and studied its 
effect on drug release (as dependent variable) at 20h for MS. A 32 factorial design was used 
for optimization purpose. 
The DSC result shows no interaction between two polymers and the drug (MS). Further, invitro 
drug release studies have shown a sustained drug release for more than 20h in upper 
gastrointestinal region (stomach). In vivo study using rabbits have shown increased AUC0-24 
(bioavailability) of prepared optimized F6 formulation as compared to the marketed sustain 
release tablet of MS. Stability study shows no comparable differences on physical parameters 
and the drug release after 3 months of accelerated stability testing.  Hence, we can conclude 
that a floating tablet containing combination of hydrophilic polymers can be used for gastric 
retention for more than 20hr which will increase the oral bioavailability of MS. 
Keywords: Metoprolol succinate, floating tablet, bioavailability, hydrophilic polymers, 
gastroretentive drug delivery. 
 
Introduction 
Metoprolol succinate is an adrenoreceptor blocking agent used as 
a β1-selective compound, [1] used mostly in the treatment of 
hypertension, coronary heart diseases and angina pectoris and has 
oral bioavailability of less than 50% mainly because of its rapid first 
pass metabolism and degradation in colon region[2,3]. Constant 
plasma levels of MS cannot be achieved by conventional tablets, 
this constant plasma levels are required for the desired therapeutic 
response. It has also been reported that MS absorption is directly 
proportional to the dose available and mainly takes place in the 
duodenum and jejunum [4]. It is said that a gastro retentive 
formulation is useful for drugs that are primarily absorbed from 
duodenum and upper jejunum regions[5]. As the half-life of 
metoprolol succinate is 3-4 h [6], multiple doses are required to 
maintain a constant plasma concentration of the drug MS so as to 
achieve the desired therapeutic effect and a better patient 
compliance. 
It is therefore, necessary to design a drug delivery system that will 
not only alleviate the shortcomings of conventional drug delivery 
system but also deliver the drug with increased bioavailability and 
improved patient compliance. The GFDDS is able to prolong the 
retention time of a dosage form in the stomach, thereby improving 
the oral bioavailability of the drug. 
It has been reported that a gastroretentive formulation was 
prepared by using three different polymers i.e sodium alginate, 
sodium carboxymethylcellulose, and magnesium 
aluminometasilicate. This formulation was successfully retained in 
the gastric region for 24h but there is no in vivo data for supporting 
its absorption pattern from stomach[7]. In another study a 
combination of sodium alginate with HPMC K100M was studied to 
extend the MS release from gastric environment, but they could not 
extend the release upto 24h for better treatment of hypertension[8]. 
One more attempt was taken by Gagan et al., to formulate a 
gastroretentive tablet by combining a range of viscosity grades of 
HPMC with some natural polymers to extend the release for more 
than 24 h but they have not mentioned any in vivo data to support 
the absorption pattern from stomach[9]. Narendra et al., also 
attempted to study the effect of different viscosities of HPMC on 
drug release of MS in the form of a bilayer floating tablet for 
24h[10]. 
HPMC is used in most of the hydrophilic extended release 
formulations due to its physiochemical properties[11]. Due to this, 
matrix tablet shows a complex release phenomenon having series 
of actions such as water penetration, swelling of polymer, 
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relaxation of macromolecular polymeric chains, drug diffusion, 
dissolution and  erosion.[12].The stability of gel layer formed 
depends on the concentration, viscosity and chemical structure of 
any polymer used in the formulation.[13] In all, the kinetics and 
mechanism of drug release depends on the swelling, erosion 
properties of polymer and the solubility of the drug molecule[14–
16]. 
Here we have studied the effect of two more hydrophilic polymers 
which were not used before in such type of studies i.e Polyethylene 
oxide WSR N-80 and hydroxyethylcellulose on drug release for 
more than 20 h from intra-gastric region (stomach) in a controlled 
manner in combination with HPMC. The higher molecular weight 
grades of PEO provides delayed drug release via the hydrophilic 
matrix formation[17,18]. Hydroxyethyl cellulose is a water-soluble 
polymer used as a thickening and viscosity increasing agent. 
The objective of this study was to develop an optimized floating 
tablet of MS and aims at(1) understanding the mechanism of drug 
release from such systems with hydrophilic (PEO and HEC) 
polymers and diluent (MCC), (2) optimization of formulation by 
response surface methodology, (3) evaluation of the oral 
bioavailability of the optimized formulation in rabbits and its 
comparison with that of a marketed SR tablet. 
 
Materials and Methods 
 
Materials 
 
MS was obtained as a gift sample from Wockhardt Limited, 
Aurangabad, Hydroxy propyl methylcellulose (HPMC)  
K15M,Hydroxyethylcellulose(HEC), Polyethylene oxide 
(PEO),Polyvinylpyrrolidone (PVP),Sodium bicarbonate (NaHCO3), 
Magnesium stearate, Microcrystalline cellulose(MCC) were 
obtained as  a gift sample from Colorcon, Ind Pvt. Ltd, Goa. All 
other solvents and reagents were purchased from Thermo fischer 
scientific Pvt. Ltd, Mumbai, and were of analytical grade. 
 
Method 
 
Calibration curve for MS was obtained in 0.1N HCL .Between the 
linearity range of (2-10µg/ml) and correlation coefficient (r2) of 
determination was obtained at 222 nm (R = 0.9985), using a UV-
Visible spectrophotometer (Shimadzu UV-1800, Japan). The 
calibration curve in 0.1NHCl was used for dissolution studies. 
 
Preformulation Studies and Optimization Process 
 
Floating tablets were prepared by a “gas generation” technique for 
retaining the tablet in the stomach using various polymers such as 
HPMC K15M, Hydroxyethylcellulose (HEC), Polyethylene oxide 
(PEO), and PVP so as to make a tablet float, in gastric 
environment for more than 20h. The polymers were evaluated with 
respect to some parameters that are: 
Determination of Viscosity of polymers 
 
Polymeric solutions of 1% (w/v) concentration of all the polymers 
were prepared in 100 ml of water. The viscosities of the prepared 
Polymeric solutions were determined by using Brookfield 
viscometer, suitable RPM and spindle were selected and viscosity 
was determined. 
 
Determination of Solubility of MS 
 
The solubility of compound was carried out in water and 0.1N HCl, 
the excess amount of drug was dissolved in 5ml of solvent. The 
solution was then subjected to ultrasonication for 30 min. It was 
then allowed to stand for 24 h at room temperature in tightly closed 
vials to attain saturation equilibrium. After 24 h the solution was 
filtered through whatman filter paper no. 41. It was then diluted up-
to mark with the solvent and its absorption was taken by UV 
spectrophotometer at 222 nm.  
 
Development and Optimization of Floating Tablets 
 
Based on the viscosity determination studies, HPMC K15M was 
selected as a matrixing agent. MS, HPMC K15M, PEO, HEC, 
sodium bicarbonate, and PVP were combined to produce tablets to 
check floating lag time (FLT, is the time required by a tablet to rise 
to the surface of a media and float), matrix integrity (MI, extent of  
swollen mass that remains intact during dissolution), and total 
floating duration to formulate a floating formulation. The direct 
compression method was used to prepare tablets and subjected to 
further evaluation. All ingredients namely MS, release-retarding 
polymers such as HPMC K15M (15,000 cps), HEC, PEO-N80, 
binder such as PVP, and diluent such as MCC were passed 
through sieve no. 60 and mixed in a polybag for 10 min, 
magnesium stearate and gas-forming agent such as sodium 
bicarbonate was then added to the mixture. Mixing continued for 
another 5 min and finally, the mixed powder blend was compressed 
by using punches of 8.5 mm on single rotary compression machine 
(Make: Rimek, Model: R&D model), to produce the desired tablets. 
The hardness of the tablets was adjusted at 4-5 kg/cm2 using a 
Monsanto hardness tester. The effects of selected variables on 
drug release was studied by using 32 factorial design, in which the 
effect of the two variables, i.e., HEC and PEO on drug dissolution 
was observed. Other variables such as amount of MS, HPMC, 
sodium bicarbonate, PVP, MCC, and magnesium stearate were 
kept constant. The three-level set includes, lower level (−1), middle 
level (0), and upper level (+1). 
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Table 1. Factorial design of selected variables 
variables Levels 
Upper (+1; mg) Middle (0; mg) Lower (−1; mg) 
X1—amount of PEO-N80 40 35 30 
X2—amount of HEC 33 28 23 
 
Table 2. Development of floating tablets prepared by 32 factorial design and their response 
 
Formula 
code 
PEO X1 HEC X2 Drug Release 
at 20th h (%) 
Matrix 
integrity 
F1 +1 +1 87.119 +++ 
F2 +1 0 90.471 +++ 
F3 +1 -1 94.604 +++ 
F4 0 +1 89.527 +++ 
F5 0 0 91.514 +++ 
F6 0 -1 99.084 +++ 
F7 -1 +1 84.620 ++ 
F8 -1 0 81.053 ++ 
F9 -1 -1 94.088 ++ 
 
All other ingredients, such as, MS=23.5 mg, HPMC K15M= 62.5 mg, NaHCO3=25 mg, MCC=50 mg, PVP=15 mg, and magnesium stearate=2.5 
mg was kept constant in all the formulations. 
 
(+++) good (matrix remains intact for more than 20 h during 
dissolution) 
(++) good (matrix remains intact for more than 16 h during 
dissolution) 
 
Evaluation of the Prepared Tablets 
 
The formulated tablets were evaluated for physical parameters, in 
vitro buoyancy and in vitro dissolution studies.  
 
Physical parameters 
 
Appearance: appearance was checked after compression with the 
naked eye or magnifying           lenses. [19] 
Thickness of tablet: Thickness of each tablet was determined with 
the help of Vernier caliper. [20] 
Tablet Weight Uniformity: An electronic balance was used to 
measure an accurate weight of each tablet and the results are 
mentioned as (mean ± SD) [21,22] 
Hardness test: To determine the hardness, each tablet was placed 
in a hardness tester and evaluated for its diametrical crushing 
strength using a hardness tester (Monsanto hardness tester) 
Friability test: The friability was determined for 10 tablets at a speed 
of 25rpm for about 4 min by using a friabilator (ERWEKA, TAR 120, 
and Germany.) The percentage friability was calculated by the 
equation. 
Friability= (initial wt. – wt. after friability) ×100 / initial wt 
Drug content: To determine the drug content, 10 tablets were 
crushed and a quantity equivalent to 100 mg of MS was added in 
0.1N HCL. This was placed for 24h to extract MS from it, then 
filtered and diluted with the media and analyzed by UV 
spectrophotometer at 222 nm. 
In vitro Buoyancy studies  
 
The invitro buoyancy was determined as follows[23]. 
Floating Lag Time (FLT): it is the time taken by a tablet to rise on 
the surface of a medium, for this it was placed in a beaker 
containing 100ml of 0.1N HCL and the time required by a tablet to 
rise to the surface of a medium was determined. 
Total Floating Time (TFT): it is the duration for which the tablet 
remains on the surface of a medium, for this a tablet was placed in 
a beaker containing 0.1N HCL and the time for which the tablet 
remains on the surface was determined.  
Matrix integrity (MI): during the total floating time the tablet was 
observed for its integrity. If not disintegrated up to 20 h, indicated 
as ‘+++’, and if disintegrated within 16 h indicated as ‘-‘. 
In vitro Dissolution Study  
A dissolution test was carried out for 20 h using the dissolution 
apparatus Elecrolab TDT- 06L according to United States 
Pharmacopoeia. [24] Each vessel contained 500 ml of 0.1N HCL, 
and the paddle apparatus with 75rpm speed was used, while the 
temperature was kept stable at 37 0C ± 0.5 0C. At every time 
interval, 5 ml of media was withdrawn and measured by UV-VIS 
spectrophotometer at 222 nm. Furthermore, 5 ml of 0.1N HCL was 
replaced to keep the volume stable. The dissolution was taken in 
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triplicate for each formulation and % release was calculated using 
PCP diss. Software. 
Differential scanning calorimetry (DSC) 
The DSC was carried out for metoprolol succinate, using a 
SHIMADZU DSC-60 plus differential scanning calorimeter. The 
system was calibrated with a high purity sample of Indium. 
Metoprolol succinate was scanned at the heating rate of 10°C/min 
over a temperature range of 50 to 250°C under nitrogen gas using 
aluminium pans. Peak transitions and enthalpy of fusion were 
determined for the samples using TA60 integrations oftware. 
Accelerated Stability Studies 
 
Accelerated stability study was carried out for 3 months according 
to international conference on Harmonization (ICH) guidelines[25]. 
To find out the quality of finished product that is the optimized 
formulation F6 under a variety of conditions such as temperature, 
humidity, time. For this the tablets were packed in an aluminium 
packaging and kept in a stability chamber maintained at 45°C 
and75% RH. At the end of every month the samples were 
withdrawn and evaluated for hardness, drug content, floating 
characteristics (FLT and MI) and % drug release at 20thh. The data 
for optimized F6 batch is tabulated in table5. 
 
Biopharmaceutical evaluation 
  
The biopharmaceutical evaluation was performed according to the 
guidelines of “committee of purpose of control and supervision of 
experiments on Animals (CPCSEA), Ministry of social justice and 
empowerment, Government of India. The pro forma B having 
protocols for animal study was approved by the IAEC (Institutional 
animal ethical committee, Y.B Chavan college of Pharmacy, 
Aurangabad, Registration no: 844/ac/04/CPCSEA).  6 adult healthy 
male rabbits weighing 2.0–3.0 kg were selected for animal study. 
Rabbits were acclimatized for 1 week in animal house and were fed 
with a standard diet, each were fasted for 24h. Then they were fed 
with optimized F6 tablets equivalent to 25mg of MS,and compared 
with that of marketed formulation of MS 25 mg (Met-XL 25mg tab). 
Water was allowed throughout the experiment. The tablet was 
given to rabbits and they swallowed it without any difficulty. Blood 
samples were collected from the marginal ear into a pre added K3 
EDTA accuvets at 0 h before giving dose and then at 1.0, 2.0, 4.0, 
6.0, 8.0, 10.0, 12.0,20.0,24.0 h after administration of the tablets. 
All the collected blood samples were centrifuged for 10 min at 2500 
rpm. The plasma sample which was obtained upon centrifuging 
was collected into another set of sample tubes and frozen until 
assayed. plasma sample which was collected at 0h was kept as 
blank and all other samples including blank were filtered through 
0.25µm membrane filter. The plasma sample was filtered through 
0.25-μm membrane filter (Millipore). From this filtered portion of 
plasma 0.2ml was collected and diluted with 1ml of acetonitrile and 
again centrifuged to obtain supernatant. The supernatant so 
obtained was collected and evaporated under nitrogen stream, and 
the residue was dissolved with 0.3ml of HPLC mobile phase. 
The MS concentration in blood plasma samples was analyzed by 
following HPLC method. Then the above prepared sample was 
injected into the column (Agilent, Eclipse XDB-C18, 150mm× 
4.6mm, 5µm) of HPLC apparatus with UV detector at detector 
wavelength 223nm. A mixture of phosphate buffer, acetonitrile 
(80:20) was used as mobile phase at a flow rate of 1 mL/min. The 
calibration curve plot was between the concentration range 5–100 
ng/ml and showed a correlation coefficient of 0.9991 
 
Pharmacokinetic study and statistical analysis  
 
The data obtained from HPLC studies were collected and a graph 
of plasma concentration of MS vs time was plotted and subjected 
to pharmacokinetic studies. Various parameters such as maximum 
plasma concentration Cmax, Tmax (it is the time to reach maximum 
concentration), and area under the curve (AUC0-24) was obtained 
from the above plot of MS concentration vs time. The AUC0-24 was 
obtained by graph pad prism software. 
 
Results and Discussion 
 
Preformulation Studies and Optimization Process 
 
As the water absorption takes place the polymeric chain begins to 
relax, as this process repeats, the polymer changes from glassy to 
rubbery phase and the tablet dimension changes in radial and axial 
directions. The lower viscosity grade HPMC disintegrates faster 
due to less water sorption to relax its polymeric chain. As the 
viscosity increases, the water sorption rate also increases, 
therefore the higher viscosity grades of HPMC such as HPMC 
K15M, K100M exhibits maximum water sorption and so the 
relaxation of its polymeric chains[26]. This shows that HPMC K15M 
showed better water sorption in comparison to HPMC K100LV, 
HPMC K4Mi.e the lower grades of HPMC. Further, drug solubility 
study shows that MS is a high solubility drug whose release cannot 
be controlled by HPMC alone therefore PEO-N80 and HEC (based 
on their viscosity) were selected to retain and retard the drug 
dissolution in stomach in a controlled manner for more than 20 h. 
 
Development and Optimization of MS Floating 
Tablets 
 
All the ingredients i.e polyethylene oxide, H.E.C, HPMC K15M, 
PVP as a binder, MCC, NaHCO3and magnesium stearate were 
mixed to obtain a perfect blend, this was then compressed to 
obtain a tablet of appropriate hardness, with varying concentration 
of polyethylene oxide, H.E.C and HPMC K15M it was found that a 
tablet which can delay or sustain the drug release of metoprolol 
succinate for more than 20h could be obtained at 35mg, 28mg and 
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62.5mg of above polymers respectively. PVP concentration was 
selected to obtain an optimized hardness and it was found to be 
15mg for a tablet to be as hard as 4kg/cm2 .Moreover trials were 
taken for invitro buoyancy of more than 16h in dissolution media 
and it was found that with the above concentration of polymers and 
binder (PVP) the amount of sodium bicarbonate which could be 
used for enhancing the in-vitro buoyancy for more than 20h is 
25mg and the amount of diluent and lubricant was taken to make 
up the bulk of the tablet. 
Combining of all the ingredients to make a tablet of appropriate 
hardness gave optimized formulae which were then used for 
factorial designing. 
A 32 factorial design was applied to study the effect of two 
independent variables on drug release. PEO (X1) and HEC(X2) 
were selected as independent variables and the dependent 
variable is the percentage of drug released at 20h (Y1). The 
physicochemical properties of the tablets are summarized in Table 
3. The hardness of the floating tablets were adjusted between 4 
and 5kg/cm2, the thickness of all tablet batches ranged from 
2.3±0.02 to 2.9±0.10 mm. All the tablet formulae showed 
acceptable physicochemical properties for weight variation, drug 
content, and friability. 
 
Table 3: Physical parameters of MS floating tablets prepared by factorial design. 
Formula 
code 
Tablet 
thickness 
(mm) 
Tablet 
weight (mg) 
Floating lag 
time (min) 
Drug content (%) Tablet 
friability (%) 
Tablet 
Hardness 
(kg/cm2) 
Total 
ﬂoating 
duration (h) 
F1 2.9±0.04 249.2±1.90 4.12±0.11 101.6±0.44 0.05±0.08 4.5 >20 
F2 2.7±0.03 245.7±2.21 3.96±0.35 108.51±0.23 0.06±0.05 4 >20 
F3 2.4±0.08 240.3±2.71 3.55±0.55 105.55±0.24 0.05±0.07  4.5 >20 
F4 2.6±0.02 244.5±1.99 3.89±0.12 101.44±0.55 0.07±0.06  5 >20 
F5 2.5±0.06 241.2±.91 3.45±1.22 99.34±0.58 0.05±0.09 4 >20 
F6 2.4±0.03 233.9±1.22 3.48±.045 92.78±0.25 0.06±0.04 4.5 >20 
F7 2.6±0.06 242.5±0.99 2.89±1.54 105.24±0.89 0.04±0.05 5 >16 
F8 2.3±0.08 235.1±1.33 2.66±0.56 97.56±0.36 0.05±0.06  4.5 >16 
F9 2.5±0.10 236.5±1.98 2.22±0.66 98.48±0.35 0.07±0.08  4 >16 
*All values are means ± SD, n=3 
 
In-Vitro Buoyancy Study 
 
The prepared tablets were based on gas generation technique in 
which sodium bicarbonate was used as a gas generating agent. 
The in vitro evaluation of primary batches by above mentioned 
method have shown that most of the prepared batches float for 
more than 16 h with 2 to 4 min of floating lag time in which the 
amount of sodium bicarbonate was between 15mg to 20mg, below 
15mg of sodium bicarbonate there is increased floating lag time 
and shorter buoyancy time and above 25mg there was no 
significant effect on buoyancy. Hence, quantity of sodium 
bicarbonate was fixed to 25mg/tab in all the formulations. 
 
Differential Scanning Calorimetry 
 
The DSC thermogram of metoprolol succinate indicates a sharp 
peak at 140.31 °C which corresponds to the melting point of 
metoprolol succinate (Fig.1). The thermogram of F6 formulation 
also exhibited the characteristic endotherm of metoprolol succinate, 
indicating crystalline state of the drug and no interaction with other 
excipients. In the thermogram of F6 formulation (Fig. 2) the 
endotherm observed at 66.81°C corresponds to melting of PEO, 
while the endotherm at 174.13°C is attributed to degradation of 
sodium bicarbonate. 
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Figure 1: DSC thermogram of metoprolol succinate pure drug 
 
 
Figure 2: DSC thermogram of F6 Formulation 
 
Drug Release Study 
 
The drug dissolution data of all 9 formulations prepared by 32 
factorial design is shown in (fig.3) it is clear from the graph that all 
the formulations have succeeded in drug release retardation for 
more than 20h, but other parameters such as FLT and MI was not 
similar in all the batches, batches F1,F4, F7, and F8 showed low 
drug dissolution profile with good FLT and MI, while F2, F3, F5, F6, 
and F9 formulations exhibited average dissolution profile and MI. 
Among all the formulations F6 formulation gave best results with 
respect to drug dissolution 99.08%, FLT 3.48±.045 min and MI 
(Table 3). 
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Figure 3: Dissolution profile of factorial batches F1–F9in 0.1 N HCL (dissolution medium) 
 
Drug Release Mechanism 
 
The regression coefficient (R2) values of dissolution data of all 
formulations were obtained by curve fitting method for zero order, 
first order, Higuchi model, and Peppas model. Most of the 
formulations follow the Higuchi and Peppas model. For the best 
formulation F6, the valueR2 of Peppas is 0.9966 (nearer to 1) 
which is dominant as compared to other models. The n value of the 
optimized formulation F6 is 0.6139 and for all other formulations is 
between 0.36 to 0.67 which shows that the drug release could be 
probably by “combination of swelling, erosion, and diffusion” [27, 
28]. 
 
Analysis of ANOVA, model equation and response 
surface plot  
 
The fit summary (Table IV) for Rel20h of MS suggested the 
quadratic relationship where some of the additional terms are 
significant (p ≤ 0.05). The regression equation represented best 
description of response after the non-significant parameters (P > 
0.05) were eliminated from the result as summarized in Table IV. 
The lack-of-fit F value indicated non significance (P > 0.05) as 
desired. The Model F-value of 13.54 implies the model is 
significant. There is only a 0.17% chance that F-value this large 
could occur due to noise. Values of "Prob> F" less than 0.0500 
indicate model terms are significant. 
In this case A, B, A2, B2 are significant model terms. 
Values greater than 0.100 indicates that the model terms are not 
significant. The ANOVA result showed only main effect (A, PEO), 
(B, HEC) the quadratic effect of A2 and B2. The interaction effect of 
two polymers (A*B) was found insignificant (P > 0.05). The other 
adequacy measures are R2 (0.906), adjusted R2 (0.839) though 
predicted R2 is not close to the adjusted R2. The adequate 
precision (13.3) indicated an adequate signal to noise ratio. 
Following equation is obtained after removing insignificant terms 
from ANOVA results. In this case A,B,A2, B2 are significant model 
terms. 
Rel = 91.3 +2.07A-4.42B-5.00A2+3.54B2  
The negative regression coefficient on B implies that an increase in 
the factor B (HEC) causes decrease in % release within the studied 
levels. As a main factor, B has positive significant effect. Release 
rate was retarded as it approaches center value because release 
(%) is low. This is evident from response surface plot (Fig. 4). In 
this model, absolute values of regression coefficients of variables 
are comparatively lower, and intercept value is very high. High R2 
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value and model F value indicate that the model is adequate and 
significant. Rel20h is adequately represented by the model 
equation. Predicted response values were in good agreement with 
the experimental response values. 
 
Table 4. ANOVA for response Rel20th hr 
Source Sum of 
squares 
df Mean square F value P Value Prob> F 
Model 222. 5 44.3 13.5 0.00175 significant 
A-PEO-N80 25.8 1 25.8 7.87 0.0263  
B-HEC 117. 1 117. 35.8 0.000552  
AB 0.983 1 0.983 0.300 0.601  
A2 69.1 1 69.1 21.1 0.00250  
B2 34.6 1 34.6 10.6 0.0140  
Residual 22.9 7 3.27    
Lack of Fit 22.9 3 7.64   Not significant 
Pure Error 0.000 4 0.000    
Cor Total 245. 12     
Coefficients with p value > 0.05 are not significant. 
Response surface for Release in 20 h 
 
 
Figure 4: Response surface plot showing the effect of polymer composition on ‘drug release in 20 h’ (Rel20thh) from GR-MS floating tablets. 
 
Accelerated stability studies  
 
Results of accelerated stability studies of optimized formulation F6 
indicate that it is stable at 400C / 75% RH up to 3Months. As there 
were no significant differences in hardness, drug content, floating 
characteristics (FLT, Matrix integrity) and % drug release at 20th 
h.(Table5). 
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Table 5. Parameters of Floating Tablets of F6 Formulation after Stability studies for 3 Months 
Time Interval Hardness 
(kg/cm2 ) 
Drug content 
(%) 
Floating characteristics % drug release 
at 20thh  
FLT (min) 
Matrix 
integrity 
Initial 4.5 92.78±0.25 3.48±.045 +++ 99.084 
1 month 4.5 92.12±0.14 3.5±.032 +++ 98.65 
2 month 4 91.45±0.27 4.1±.055 +++ 97.67 
3 month 4 91.12±0.45 4.3±.043 +++ 97.12 
 
Pharmacokinetic Parameters and Bioavailability 
studies of Floating Tablets of MS 
 
After oral administration of GR-MS floating F6 formulation and 
marketed SR matrix tablets, the in vivo data was obtained and 
plasma concentration vs time was plotted in (figure.5), from this plot 
different pharmacokinetic parameters were studied and 
summarized in table 6. The pharmacokinetic parameters such as 
Tmax and AUC are related to the rate and extent of absorption, 
respectively while Cmax is related to both the processes. The 
extent of absorption is a characteristic feature of any formulation. 
Thus AUC can be studied for comparative analysis of any two 
formulations. The AUC for the studied formulations has shown 
significantly different values. But there was no significant difference 
between t1/2, Tmax and Cmax. AUC0-24 of the F6 floating tablet 
was significantly higher than those of marketed SR matrix tablet. 
Therefore, MS floating tablets can successfully increase the oral 
bioavailability of Metoprolol succinate. 
 
 
Figure. 5. The plasma concentration vs. time proﬁle of F6 tablets and the marketed SR matrix tablets. 
 
Table 6. Pharmacokinetic Parameters and Bioavailability of F6 Floating Tablets and marketed SR matrix tablets 
 
Formulation Tmax (h) Cmax (ng/ml) AUC 
(ng h-1 ml-1) 
marketed SR matrix tablet 4.0±0.87 82±13 606.45±0.12 
F6 tablet 4.1±0.23 85±22 1110.74±0.234 
 
Conclusions  
 
Results of this study demonstrated that combination of two new 
hydrophilic polymers in combination with HPMC can be 
successfully used to formulate a gastroretentive floating tablet of 
MS. Development of floating tablet is made through preparation, 
characterization, dissolution study, and in vivo studies for 
determining  bioavailability . The new GR matrix tablet (F6, 25 mg) 
sustained the release of drug up to 20 h by floating in the gastric 
region. The developed formulations are stable, and there is no 
significant degradation of the drug during development process, 
storage, and stability studies. The developed floating drug delivery 
system has the potential to enhance the oral bioavailability of MS 
and might be a suitable alternative to improve its systemic 
availability. The successful outcome of present study supports for 
further studies in human volunteers. 
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